生物制品治疗类风湿关节炎评价新视角

doi:10.19586/j.2095-2341.2023.0135

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 55-59.DOI: 10.19586/j.2095-2341.2023.0135

• 生物制品研发与技术专题 • 上一篇下一篇

生物制品治疗类风湿关节炎评价新视角

马小涵¹^,²(), 黄丽晶¹^,², 汪飞¹^,², 李晨辉¹^,²()

^1.河北菲尼斯生物技术有限公司，河北省自身免疫病药物研究重点实验室，石家庄 050035
^2.石家庄自身免疫药物技术创新中心，石家庄 050035

收稿日期:2023-10-23 接受日期:2024-01-04 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 李晨辉
作者简介:马小涵 E-mail: 1005603595@qq.com；
基金资助:
石家庄市科技计划项目(221200013A)

A New Perspective to Evaluate the Treatment of Rheumatoid Arthritis with Biological Products

Xiaohan MA¹^,²(), Lijing HUANG¹^,², Fei WANG¹^,², Chenhui LI¹^,²()

^1.Hebei Key Laboratory of Autoimmunity Disease Drug Research，Hebei Fitness Biotechnology Co. ，Ltd. ，Shijiazhuang 050035，China
^2.Shijiazhuang Technology Innovation Centre of Autoimmune Disease Drug，Shijiazhuang 050035，China

Received:2023-10-23 Accepted:2024-01-04 Online:2024-01-25 Published:2024-02-05
Contact: Chenhui LI

摘要/Abstract

摘要：

类风湿关节炎（rheumatoid arthritis，RA）是一种广泛存在的系统性自身免疫性疾病，以关节免疫功能紊乱伴随严重滑膜炎和关节侵蚀为特征，进一步发展会导致进行性残疾。目前，临床上针对RA的治疗药物以缓解病情的抗类风湿药物（disease-modifying anti-rheumatic drugs，DMARDs）为主，包括传统合成DMARDs（traditional synthetic DMARDs，csDMARDs）、生物类DMARDs（biological DMARDs，bDMARDs）和靶向合成DMARDs（targeted synthetic DMARDs，tsDMARDs），此外还包括非甾体类抗炎药（nonsteroidal antiinflammatory drugs，NSAIDs）及糖皮质激素类药物（glucocorticoids，GCs）。其中，bDMARDs和tsDMARDs已成为RA市场的绝对主力，但因其使用周期长且存在一定的安全性问题，无法达到有效的持续缓解状态，停药后往往会有复发可能，进一步限制了临床应用。综述了临床上主要RA治疗药物及停药后复发情况的研究进展，以期为临床用药周期及方式提供有效的理论依据和新思路。

关键词: 类风湿关节炎, 改善病情抗风湿药, 小分子激酶抑制剂, 停药复发情况

Abstract:

Rheumatoid arthritis （RA） is a widespread systemic autoimmune disease characterized by joint immune dysfunction with severe synovitis and joint erosion， which can further lead to progressive disability. At present， the main therapeutic drugs for RA in clinical practice are disease modifying anti rheumatoid drugs （DMARDs） that alleviate the condition， including traditional synthetic DMARDs （csDMARDs）， biological DMARDs （bDMARDs）， and targeted synthetic DMARDs （tsDMARDs）. In addition， non steroidal anti-inflammatory drugs （NSAIDs） and glucocorticoids （GCs） are also included. Among them， bDMARDs and tsDMARDs have become the absolute mainstay of the RA market， but due to their long usage cycle and some safety issues， it is impossible to achieve effective and sustained relief， and the phenomenon of relapse often occurs after drug withdrawal， which further limits the clinical application. The article reviewed the research progress on the recurrence of major RA treatment drugs after discontinuation in clinical practice， in order to provide an effective theoretical basis and new ideas for the clinical drug cycle and method.

Key words: rheumatoid arthritis, disease-modifying anti-rheumatic drugs, small molecule kinase inhibitors, relapse after drug withdrawal

中图分类号:

Q814

马小涵, 黄丽晶, 汪飞, 李晨辉. 生物制品治疗类风湿关节炎评价新视角[J]. 生物技术进展, 2024, 14(1): 55-59.

Xiaohan MA, Lijing HUANG, Fei WANG, Chenhui LI. A New Perspective to Evaluate the Treatment of Rheumatoid Arthritis with Biological Products[J]. Current Biotechnology, 2024, 14(1): 55-59.

图/表 1

参考文献 19

1	孙婧,刘丹,慧文其.计算机模拟设计治疗急性关节炎的秋水仙碱生物电子等排抑制剂研究[J].生物技术进展,2019,9(1):84-88.
	SUN J, LIU D, HUI W Q. Study on design of colchicine inhibitors of tubulin for the treatment of rheumatoid arthritis based on computer simulation[J]. Curr. Biotechnol., 2019, 9(1): 84-88.
2	曾仙月,王东军,孙璇,等.国内类风湿关节炎临床诊疗指南与专家共识方法学质量系统评价[J].世界科学技术-中医药现代化,2023,25(4):1425-1433.
	ZENG X Y, WANG D J, SUN X, et al.. Systematic evaluation of clinical diagnosis and treatment guidelines and expert consensus methodology quality of rheumatoid arthritis in China[J]. Mod. Tradit. Chin. Med. Mater. Med. World Sci. Technol., 2023, 25(4): 1425-1433.
3	朱丽芳,俸一然,许东云.类风湿关节炎患者生存质量的研究进展[J].风湿病与关节炎,2018,7(4):76-80.
	ZHU L F, FENG Y R, XU D Y. Research progress in quality of life of patients with rheumatoid arthritis[J]. Rheum. Arthritis, 2018, 7(4): 76-80.
4	曾小峰,朱松林,谭爱春,等.我国类风湿关节炎疾病负担和生存质量研究的系统评价[J].中国循证医学杂志,2013,13(3):300-307.
	ZENG X F, ZHU S L, TAN A C, et al.. Disease burden and quality of life of rheumatoid arthritis in China: a systematic review[J]. Chin. J. Evid. Based Med., 2013, 13(3): 300-307.
5	中华医学会风湿病学分会.2018中国类风湿关节炎诊疗指南[J].中华内科杂志,2018,57(4):242-251.
	Rheumatology Branch of the Chinese Medical Association. Chinese guideline for the diagnosis and treatment of rheumatoid arthritis[J]. Chin. J. Intern. Med., 2018, 57(4): 242-251.
6	CHATZIDIONYSIOU K, TURESSON C, TELEMAN A, et al.. A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission[J/OL]. RMD Open, 2016, 2(1): e000133[2024-01-04]. .
7	HARIGAI M, TAKEUCHI T, TANAKA Y, et al.. Discontinuation of adalimumab treatment in rheumatoid arthritis patients after achieving low disease activity[J]. Mod. Rheumatol., 2012, 22(6): 814-822.
8	SMOLEN J S, NASH P, DUREZ P, et al.. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial[J]. Lancet Lond. Engl., 2013, 381(9870): 918-929.
9	VAN VOLLENHOVEN R F, ØSTERGAARD M, LEIRISALO-REPO M, et al.. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis[J]. Ann. Rheum. Dis., 2016, 75(1): 52-58.
10	EMERY P, BURMESTER G R, BYKERK V P, et al.. Retreatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study[J/OL]. RMD Open, 2019, 5(1): e000840[2024-01-04]. .
11	HUIZINGA T W, CONAGHAN P G, MARTIN-MOLA E, et al.. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study[J]. Ann. Rheum. Dis., 2015, 74(1): 35-43.
12	NISHIMOTO N, AMANO K, HIRABAYASHI Y, et al.. Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study[J]. Mod. Rheumatol., 2014, 24(1): 17-25.
13	KUBO S, MIYAZAKI Y, AMANO K, et al.. Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study[J/OL]. RMD Open, 2023, 9(2): e003029[2023-01-04]. .
14	KAINE J, TESSER J, TAKIYA L, et al.. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis[J]. Clin. Rheumatol., 2020, 39(7): 2127-2137.
15	ALIVERNINI S, FIRESTEIN G S, MCINNES I B. The pathogenesis of rheumatoid arthritis[J]. Immunity, 2022, 55(12): 2255-2270.
16	FAUTREL B. Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?[J]. Nat. Rev. Rheumatol., 2023, 19(10): 611-612.
17	ALBANI S, KOFFEMAN E C, PRAKKEN B. Induction of immune tolerance in the treatment of rheumatoid arthritis[J]. Nat. Rev. Rheumatol., 2011, 7(5): 272-281.
18	蔚丹,马云龙,万方,等.mRNA疫苗的研究及应用进展[J].生物技术进展,2023,13(4):492-498.
	YU D, MA Y L, WAN F, et al.. Advances on research and application of mRNA vaccines[J]. Curr. Biotechnol., 2023, 13(4): 492-498.
19	杨懿祺,张志高,游小龙,等.抗体药物的发展与应用[J].生物技术进展,2022,12(3):358-365.
	YANG Y Q, ZHANG Z G, YOU X L, et al.. Development and application of monoclonal antibody-based drug[J]. Curr. Biotechnol., 2022, 12(3): 358-365.

[1]	李薇, 石爱民, 焦博, 王强. 乙酰化花生球蛋白载酶颗粒的制备及表征[J]. 生物技术进展, 2023, 13(5): 771-778.
[2]	周亚梅, 刘佳, 陆丹, 孔庆新. 脂肪酶的固定化及其在药物合成中的应用进展[J]. 生物技术进展, 2023, 13(2): 220-227.

生物制品治疗类风湿关节炎评价新视角

A New Perspective to Evaluate the Treatment of Rheumatoid Arthritis with Biological Products

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 19

相关文章 2

编辑推荐

Metrics

本文评价